Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights- July 2017


Hepatic uptake is a key process determining the intrinsic clearance of a molecule and is important in the accurate in vitro to in vivo extrapolation of hepatic clearance. Through its parent company, Evotec, Cyprotex can now offer a hepatic uptake service using human or rat hepatocytes. Learn more about this service below.

In June, Cyprotex scientists attended the European ISSX meeting in Cologne, and presented two posters at the event - one on research in the field of drug transporters and the other on our chemPKTM software which predicts pharmacokinetics directly from structure. Download the posters below.

Finally, we would like to share with you some of the highlights from the Evotec Group.

New hepatic uptake assay

Cyprotex's parent company, Evotec, have recently introduced a hepatic uptake assay to improve the in vitro to in vivo correlation of intrinsic clearance.

Find out more

Hepatic uptake assay
Download our recent posters from ISSX Cologne 2017

Cyprotex presented research at the European ISSX meeting in Cologne. Download the posters for free.

Estrone 3-sulfate as a surrogate breast cancer resistance protein (BCRP) in vitro probe substrate for assessing drug-drug interaction risk with rosuvastatin.

Download poster

PBPK modelling for predicting human pharmacokinetics in drug discovery.

Download poster

Download posters
Highlights from our parent company, Evotec

Learn more about Evotec's collaboration with, and investment in, Facio Therapies to develop new therapies for FSHD, a progressive muscle wasting disease.

Learn more

A second round of funding for LAB282, Evotec's partnership with Oxford University and Oxford Sciences Innovation, has been secured allowing acceleration of drug discovery projects from five different therapeutics areas.

Learn more

'A Brand New Outlook on Induced Pluripotent Stem Cells'. Read Evotec's recent article to learn more about patient-derived iPSC-derived cells and how they are being used in drug discovery .

Learn more

Evotec and Bayer extend alliance and advance endometriosis programme into Phase I clinical development.

Learn more

Learn more

Learn more
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.